Erratum: Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): A randomised, open-label, multicentre, phase 3 trial (The Lancet (2012) 379 (633-640))

J. Baselga; I. Bradbury; H. Eidtmann

doi:10.1016/S0140-6736(12)60268-2

Erratum: Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): A randomised, open-label, multicentre, phase 3 trial (The Lancet (2012) 379 (633-640))

J. Baselga, I. Bradbury, H. Eidtmann

Business, Management and Accounting

Research output: Contribution to journal › Comment/debate › peer-review

5 Citations (Scopus)

Original language	English
Pages (from-to)	616
Number of pages	1
Journal	The Lancet
Volume	379
Issue number	9816
DOIs	https://doi.org/10.1016/S0140-6736(12)60268-2
Publication status	Published - Feb 2012

ASJC Scopus Subject Areas

General Medicine

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/S0140-6736(12)60268-2

Cite this

@article{257091b308de445f94a6c6a2f16fb571,

title = "Erratum: Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): A randomised, open-label, multicentre, phase 3 trial (The Lancet (2012) 379 (633-640))",

author = "J. Baselga and I. Bradbury and H. Eidtmann",

year = "2012",

month = feb,

doi = "10.1016/S0140-6736(12)60268-2",

language = "English",

volume = "379",

pages = "616",

journal = "The Lancet",

issn = "0140-6736",

publisher = "Elsevier Limited",

number = "9816",

}

TY - JOUR

T1 - Erratum

T2 - Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): A randomised, open-label, multicentre, phase 3 trial (The Lancet (2012) 379 (633-640))

AU - Baselga, J.

AU - Bradbury, I.

AU - Eidtmann, H.

PY - 2012/2

Y1 - 2012/2

UR - http://www.scopus.com/inward/record.url?scp=84857211691&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84857211691&partnerID=8YFLogxK

U2 - 10.1016/S0140-6736(12)60268-2

DO - 10.1016/S0140-6736(12)60268-2

M3 - Comment/debate

AN - SCOPUS:84857211691

SN - 0140-6736

VL - 379

SP - 616

JO - The Lancet

JF - The Lancet

IS - 9816

ER -

Erratum: Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): A randomised, open-label, multicentre, phase 3 trial (The Lancet (2012) 379 (633-640))

ASJC Scopus Subject Areas

UN SDGs

Access to Document

Other files and links

Cite this